Technical Analysis for IRWD - Ironwood Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 18.44 -0.75% -0.14
IRWD closed down 0.75 percent on Friday, June 15, 2018, on 1.77 times normal volume.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical IRWD trend table...

Date Alert Name Type % Chg
Jun 15 Doji - Bearish? Reversal 0.00%
Jun 15 BB Squeeze Ended Range Expansion 0.00%
Jun 15 Upper Bollinger Band Touch Strength 0.00%
Jun 14 MACD Bullish Signal Line Cross Bullish -0.75%
Jun 14 Bollinger Band Squeeze Range Contraction -0.75%
Jun 13 50 DMA Support Bullish 1.99%
Jun 13 Bollinger Band Squeeze Range Contraction 1.99%
Jun 13 Outside Day Range Expansion 1.99%
Jun 12 Bollinger Band Squeeze Range Contraction 4.24%
Jun 12 NR7 Range Contraction 4.24%

Older signals for IRWD ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Ironwood Pharmaceuticals, Inc., an entrepreneurial pharmaceutical company, discovers, develops, and commercializes human therapeutic products. The company's lead product candidate, linaclotide, a guanylate cyclase type-C agonist for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) gastrointestinal disorders under the LINZESS name in the United States and Constella name in the European Union. It also has a pipeline focused on the research and development of early development candidates and discovery research programs in various therapeutic areas, including gastrointestinal diseases, central nervous system disorders, allergic conditions, and cardiovascular diseases. Ironwood Pharmaceuticals has collaboration and license agreements with Forest Laboratories, Inc. to develop and commercialize linaclotide in North America; Almirall, S.A to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal conditions; Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal conditions in Japan, South Korea, Taiwan, Thailand, the Philippines, and Indonesia; and AstraZeneca AB to co-develop and co-commercialize linaclotide in China, including Hong Kong and Macau. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.
Is IRWD a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 19.94
52 Week Low 12.89
Average Volume 1,531,424
200-Day Moving Average 15.8996
50-Day Moving Average 17.6888
20-Day Moving Average 17.7545
10-Day Moving Average 17.845
Average True Range 0.6641
ADX 13.98
+DI 25.48
-DI 20.54
Chandelier Exit (Long, 3 ATRs ) 17.1677
Chandelier Exit (Short, 3 ATRs ) 18.6023
Upper Bollinger Band 18.6899
Lower Bollinger Band 16.8191
Percent B (%b) 0.87
BandWidth 10.537047
MACD Line 0.1497
MACD Signal Line 0.0887
MACD Histogram 0.061
Fundamentals Value
Market Cap 2.76 Billion
Num Shares 150 Million
EPS -0.98
Price-to-Earnings (P/E) Ratio -18.82
Price-to-Sales 8.05
Price-to-Book 441.52
PEG Ratio -0.24
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.15
Resistance 3 (R3) 19.15 18.92 19.03
Resistance 2 (R2) 18.92 18.74 18.92 18.99
Resistance 1 (R1) 18.68 18.63 18.57 18.68 18.95
Pivot Point 18.45 18.45 18.39 18.45 18.45
Support 1 (S1) 18.21 18.27 18.10 18.21 17.93
Support 2 (S2) 17.98 18.16 17.98 17.89
Support 3 (S3) 17.74 17.98 17.85
Support 4 (S4) 17.74